Urinary Tract Infections
-
Vanderbilt biochemists contribute to breakthrough discovery of first new antibacterial class in decades
Led by Neil Osheroff, Vanderbilt researchers are the first to undertake a systematic analysis of the mechanism of action of geoptidacin. Gepotidacin is poised to become the first new class of antibacterials to be approved for use in humans in decades. Read MoreMar. 26, 2024
-
Vanderbilt biochemists join international researchers in discovery of the first new antibiotic for urinary tract infections in more than 20 years
Neil Osheroff, John Coniglio Chair in Biochemistry and professor of biochemistry and medicine, is part of an international research collaboration resulting in what is on track to be the first new antibiotic treatment for uncomplicated urinary tract infections in more than 20 years. “We now have a direct path connecting… Read MoreJan. 18, 2023